GAMMA Investing LLC Has $107,000 Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

GAMMA Investing LLC increased its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 369.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,799 shares of the company’s stock after purchasing an additional 5,352 shares during the quarter. GAMMA Investing LLC’s holdings in Dr. Reddy’s Laboratories were worth $107,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in RDY. Farther Finance Advisors LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 43.2% during the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after purchasing an additional 137 shares during the period. Venturi Wealth Management LLC bought a new position in Dr. Reddy’s Laboratories during the third quarter valued at approximately $60,000. Van ECK Associates Corp raised its position in Dr. Reddy’s Laboratories by 64.3% during the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock valued at $64,000 after acquiring an additional 322 shares in the last quarter. Glenmede Trust Co. NA bought a new position in Dr. Reddy’s Laboratories during the third quarter valued at approximately $207,000. Finally, Waldron Private Wealth LLC bought a new position in Dr. Reddy’s Laboratories during the third quarter valued at approximately $236,000. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RDY has been the topic of several recent research reports. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. Finally, Barclays cut their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Trading Down 2.5 %

NYSE:RDY opened at $15.41 on Friday. Dr. Reddy’s Laboratories Limited has a 12 month low of $13.43 and a 12 month high of $16.89. The firm has a market cap of $12.86 billion, a price-to-earnings ratio of 24.62 and a beta of 0.51. The company has a quick ratio of 1.36, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The company’s 50 day moving average is $14.83 and its 200-day moving average is $15.53.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.